Setterwalls has advised Iconovo in connection with an oversubscribed rights issue of shares

Setterwalls has advised Iconovo AB in, listed on Nasdaq First North Growth Market, in connection with an oversubscribed rights issue of shares.

Iconovo develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals.

Through the rights issue, which was subscribed to approximately 114.4 percent, Iconovo receives issue proceeds of approximately SEK 36.6 million before issue costs.